Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis

Clinical and Experimental Rheumatology

Volumn 29, Issue 2, 2011, Pages 322-330

  Stoll, Matthew L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adaptive immunity; Ankylosing spondylitis; Inflammatory bowel diseases; Innate immunity; Spondylarthritis

Indexed keywords

ADAPTIVE IMMUNITY; ANKYLOSING SPONDYLITIS; CHRONIC ARTHRITIS; CHRONIC INFLAMMATION; HUMAN; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; IMMUNE SYSTEM; IMMUNOLOGY; SPONDYLARTHRITIS;

ADAPTIVE IMMUNITY; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; SPONDYLARTHRITIS;

EID: 79959505927     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (162)

1. BORGHESI L, MILCAREK C: Innate versus adaptive immunity: a paradigm past its prime? Cancer Res 2007; 67: 3989-93.
2. McGONAGLE DA, DICKIE ALJ, MCDERMOTT MF: An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr Res 2009.
3. SILVERSTEIN AM: Autoimmunity versus horror autotoxicus: the struggle for recognition . Nat Immunol 2001; 2: 279-81.
4. BURNET FM: A modification of Jerne's theory of antibody production using the concept of clonal selection. Aust J Sci 1955; 20: 67-77.
5. ALBIGER B, DAHLBERG S, HENRIQUES-NORMARK B, NORMARK S: Role of the innate immune system in host defence against bacterial infections: focus on the Toll-like receptors. J Intern Med 2007; 261: 511-28.
6. FOELL D, WITTKOWSKI H, ROTH J: Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat Clin Pract Rheumatol 2007; 3: 382-90.
7. AREND WP: The innate immune system in rheumatoid arthritis. Arthritis Rheum 2001; 44: 2224-34.
8. KATARIA RK, BRENT LH: Spondyloarthropathies. Am Fam Physician 2004; 69: 2853-60.
9. DAVIS JC JR, MEASE PJ: Insights into the pathology and treatment of spondylarthritis: from the bench to the clinic. Semin Arthritis Rheum 2008; 38: 83-100.
10. INMAN RD: Innate immunity of spondyloarthritis: the role of toll-like receptors. Adv Exp Med Biol 2009; 649: 300-9.
11. MASTERS SL, SIMON A, AKSENTIJEVICH I, KASTNER DL: Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 2009; 27: 621-68.
12. DE RYCKE L, KRUITHOF E, VANDOOREN B. TAK PP, BAETEN D: Pathogenesis of spondylarthritis: insights from synovial membrane studies. Curr Rheumatol Rep 2006; 8: 275-82.
13. INMAN RD, EL-GABALAWY HS: The immunology of ankylosing spondylitis and rheumatoid arthritis: a tale of similarities and dissimilarities. Clin Exp Rheumatol 2009; 27(4 Suppl. 55): S26-32.
14. LORIES RJ, BAETEN DL: Differences in pathophysiology between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27 (4 Suppl. 55): S10-4.
15. BENJAMIN R, PARHAM P: Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 1990; 11: 137-42.
16. BREWERTON DA, HART FD, NICHOLLS A, CAFFREY M, JAMES DC, STURROCK RD: Ankylosing spondylitis and HL-A 27. Lancet 1913; 1: 904-7.
17. SCHLOSSTEIN L, TERASAKI PI, BLUESTONE PEARSON RCM: High association of an HLA antigen, W27, with ankylosing spondylitis. N Engl J Med 1973; 288: 704-6.
18. BENJAMIN R, PARHAM P: HLA-B27 and disease: a consequence of inadvertent antigen presentation? Rheum Dis Clin North Am 1992; 18: 11-21.
19. COLBERT RA, DELAY ML, LAYH-SCHMITT G, SOWDERS DP: HLA-B27 misfolding and spondyloarthropathies. Prion 2009; 3: 15-26.
20. Mear JP, Schreiber KL, Munz C et al.: Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol 1999; 163: 6665-70.
21. TURNER MJ, SOWDERS DP, DELAY ML et al.: HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. J Immunol 2005; 175: 2438-48.
22. Taurog JD, Dorris ML, Satumtira N et al.: Spondylarthritis in HLA-B27/human beta2-microglobulin-transgenic rats is not prevented by lack of CD8. Arthritis Rheum 2009; 60: 1977-84.
23. Khare SD, Luthra HS, David CS: Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking beta 2-microglobulin: a model of human spondyloarthropathies. J Exp Med 1995; 182: 1153-8.
24. TAUROG JD: The mystery of HLA-B27: if it isn't one thing, it's another. Arthritis Rheum 2007; 56: 2478-81.
25. SHEEHAN NJ: HLA-B27: what's new? Rheumatology (Oxford) 49: 621-31.
26. GALOCHA B, DE CASTRO JA: Folding of HLA-B27 subtypes is determined by the global effect of polymorphic residues and shows incomplete correspondence to ankylosing spondylitis. Arthritis Rheum 2008; 58: 401-12.
27. SHIAU MY, LO MK, CHANG CP, YANG TP, HO KT, CHANG YH: Association of tumour necrosis factor alpha promoter polymorphisms with ankylosing spondylitis in Taiwan. Ann Rheum Dis 2007; 66: 562-3.
28. VARGAS-ALARCON G, CASASOLA-VARGAS J, RODRIGUEZ-PEREZ JM et al.: Tumor necrosis factor-alpha promoter polymorphisms in Mexican patients with spondylarthritis. Hum Immunol 2006; 67: 826-32.
29. RAHMAN P, SIANNIS F, BUTT C et al.: TNF-alpha polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis 2006; 65: 919-23.
30. CARTER KW, PLUZHNIKOV A, TIMMS AE et al.: Combined analysis of three whole genome linkage scans for Ankylosing Spondylitis. Rheumatology (Oxford) 2007; 46: 763-71.
31. RAHMAN P, SUN S, PEDDLE L et al.: Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 2006; 54: 2321-5.
32. MAKSYMOWYCH WP, RAHMAN P, REEVE JP, GLADMAN DD, PEDDLE L, INMAN RD: Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. Arthritis Rheum 2006; 54: 974-85.
33. TIMMS AE, CRANE AM, SIMS AM et al.: The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet 2004; 75: 587-95.
34. MAKSYMOWYCH WP, REEVE JP, REVEILLE JD et al.: High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of- flight mass spectrometry. Arthritis Rheum 2003; 48: 2011-8.
35. VAN DER PAARDT M, CRUSIUS JB, GARCIA-GONZALEZ MA et al.: Interleukin-1 beta and interleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis. Rheumatology (Oxford) 2002; 41: 1419-23.
36. MCGARRY F, NEILLY J, ANDERSON N, STURROCK R, FIELD M: A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatology (Oxford) 2001; 40: 1359-64.
37. SNELGROVE T, LIM S, GREENWOOD C et al.: Association of toll-like receptor 4 variants and ankylosing spondylitis: a case-control study. J Rheumatol 2007; 34: 368-70.
38. REVEILLE JD, SIMS AM, DANOY P et al.: Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 2010; 42: 123-7.
39. BROWN MA: Genetics of ankylosing spondylitis. Curr Opin Rheumatol 2010; 22: 126-32.
40. ZINOVIEVA E, BOURGAIN C, KADI A et al.: Comprehensive linkage and association analyses identify haplotype, near to the TNFSF15 gene, significantly associated with spondylarthritis. PLoS Genet 2009; 5: e1000528.
41. POINTON JJ, HARVEY D, KARADERI T et al.: The chromosome 16q region associated with ankylosing spondylitis includes the candidate gene tumour necrosis factor receptor type 1-associated death domain (TRADD). Ann Rheum Dis 2010; 69: 1243-6.
42. DAMSKER JM, HANSEN AM, CASPI RR: Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci 1183: 211-21.
43. ABRAHAM C, CHO J: Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 1090-100.
44. GASTON JS, JARVIS LB, ZHANG L, GOODALL JC: Dendritic cell: T-cell interactions in spondyloarthritis. Adv Exp Med Biol 2009; 649: 263-76.
45. KAMADA N, HISAMATSU T, OKAMOTO S et al.: Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 2008; 118: 2269-80.
46. LITTMAN DR, RUDENSKY AY: Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010; 140: 845-58.
47. CICCIA F, BOMBARDIERI M, PRINCIPATO A et al.: Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 2009; 60: 955-65.
48. CHOU CT, HUO AP, CHANG HN, TSAI CY, CHEN WS, WANG HP: Cytokine production from peripheral blood mononuclear cells in patients with ankylosing spondylitis and their first-degree relatives. Arch Med Res 2007; 38: 190-5.
49. CANDIA L, MARQUEZ J, HERNANDEZ C, ZEA AH, ESPINOZA LR: Toll-like receptor2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity? J Rheumatol 2007; 34: 374-9.
50. KRUITHOF E, DE RYCKE L, VANDOOREN B et al.: Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum 2006; 54: 1795-804.
51. BAETEN D, DEMETTER P, CUVELIER CA et al.: Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 2002; 196: 343-50.
52. ANTONI CE, KAVANAUGH A, KIRKHAM B et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52: 1227-36.
53. BRANDT J, KHARIOUZOV A, LISTING J et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667-75.
54. CALIN A, DIJKMANS BA, EMERY P et al.: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594-600.
55. GENOVESE MC, MEASE PJ, THOMSON GT et al.: Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007; 34: 1040-50.
56. BRAUN J, DEODHAR A, DIJKMANS B et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008; 59: 1270-8.
57. HAIBEL H, RUDWALEIT M, LISTING J, SIEPER J: Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005; 64: 296-8.
58. TAN AL, MARZO-ORTEGA H, O'CONNOR P, FRASER A, EMERY P, McGONAGLE D: Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004; 63: 1041-5.
59. TANAKA T, KUWAHARA Y, SHIMA Y et al.: Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum 2009; 61: 1762-4.
60. VAN DER HEIJDE D, MAKSYMOWYCH WP: Spondylarthritis: state of the art and future perspectives. Ann Rheum Dis 2010; 69: 949-54.
61. LOPEZ DE CASTRO JA: The HLA-B27 peptidome: building on the cornerstone. Arthritis Rheum 2010; 62: 316-9.
62. TAM LS, GU J, YU D: Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 2010; 6: 399-405.
63. SCOFIELD RH, KURIEN B, GROSS T, WARREN WL, HARLEY JB: HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancet 1995; 345: 1542-4.
64. EWING C, EBRINGER R, TRIBBICK G, GEYSEN HM: Antibody activity in ankylosing spondylitis sera to two sites on HLA B27.1 at the MHC groove region (within sequence 65-85), and to a Klebsiella pneumoniae nitrogenase reductase peptide (within sequence 181-199). J Exp Med 1990; 171: 1635-47.
65. CRAGNOLINI JJ, DE CASTRO JA: Identification of endogenously presented peptides from Chlamydia trachomatis with high homology to human proteins and to a natural self-ligand of HLA-B27. Mol Cell Proteomics 2008; 7: 170-80.
66. RAMOS M, ALVAREZ I, SESMA L, LOGEAN A, ROGNAN D, LOPEZ DE CASTRO JA: Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem 2002; 277: 37573-81.
67. BEN DROR L, BARNEA E, BEER I, MANN M, ADMON A: The HLA-B*2705 peptidome. Arthritis Rheum 2010; 62: 420-9.
68. LOPEZ DE CASTRO JA: The HLA-B27 peptidome: Building on the cornerstone. Arthritis Rheum 62: 316-9.
69. PIMENTEL-SANTOS FM, LIGEIRO D, MATOS M et al.: Association of IL23R and ERAP1 genes with ankylosing spondylitis in a Portuguese population. Clin Exp Rheumatol 2009; 27: 800-6.
70. MAKSYMOWYCH WP, INMAN RD, GLADMAN DD, REEVE JP, POPE A, RAHMAN P: Association of a specific ERAP1/ARTS1 haplotype with disease susceptibility in ankylosing spondylitis. Arthritis Rheum 2009; 60: 1317-23.
71. DAVIDSON SI, WU X, LIU Y et al.: Association of ERAP1, but not IL23R, with ankylosing spondylitis in a Han Chinese population. Arthritis Rheum 2009; 60: 3263-8.
72. HAMMER GE, GONZALEZ F, CHAMPSAUR M, CADO D, SHASTRI N: The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol 2006; 7: 103-12.
73. CUI X, HAWARI F, ALSAATY S et al.: Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. J Clin Invest 2002; 110: 515-26.
74. HAROON N, TSUI FW, CHIU B, TSUI HW, INMAN RD: Serum cytokine receptors in ankylosing spondylitis: relationship to inflammatory markers and endoplasmic reticulum aminopeptidase polymorphisms. J Rheumatol 2010; 37: 1907-10.
75. TSUI FW, HAROON N, REVEILLE JD et al.: Association of an ERAP1 ERAP2 haplotype with familial ankylosing spondylitis. Ann Rheum Dis 2010; 69: 733-6.
76. LEROUX JY, GUERASSIMOV A, CARTMAN A et al.: Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratan sulfate in vitro and in vivo. J Clin Invest 1996; 97: 621-32.
77. MIKECZ K, GLANT TT, POOLE AR: Immunity to cartilage proteoglycans in BALB/c mice with progressive polyarthritis and ankylosing spondylitis induced by injection of human cartilage proteoglycan. Arthritis Rheum 1987; 30: 306-18.
78. SHI S, CIURLI C, CARTMAN A, PIDOUX I, POOLE AR, ZHANG Y: Experimental immunity to the G1 domain of the proteoglycan versican induces spondylitis and sacroiliitis, of a kind seen in human spondylarthropathies. Arthritis Rheum 2003; 48: 2903-15.
79. KUON W, KUHNE M, BUSCH DH et al.: Identification of novel human aggrecan T cell epitopes in HLA-B27 transgenic mice associated with spondyloarthropathy. J Immunol 2004; 173: 4859-66.
80. KIM TJ, KIM TH, LEE HJ, LEE B, POOLE RA, INMAN RD: T-cell responses to versican in ankylosing spondylitis. Rheumatol Int 2009.
81. ZOU J, APPEL H, RUDWALEIT M, THIEL A, SIEPER J: Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis. Ann Rheum Dis 2005; 64: 722-9.
82. KIM HJ, KRENN V, STEINHAUSER G, BEREK C: Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol 1999; 162: 3053-62.
83. REVELL PA, MAYSTON V: Histopathology of the synovial membrane of peripheral joints in ankylosing spondylitis. Ann Rheum Dis 1982; 41: 579-86.
84. VOSWINKEL J, WEISGERBER K, PFREUNDSCHUH M, GAUSE A: B lymphocyte involvement in ankylosing spondylitis: the heavy chain variable segment gene repertoire of B lymphocytes from germinal center-like foci in the synovial membrane indicates antigen selection. Arthritis Res 2001; 3: 189-95.
85. SCHRODER AE, SIEPER J, BEREK C: Antigen-dependent B cell differentiation in the synovial tissue of a patient with reactive arthritis. Mol Med 1997; 3: 260-72.
86. APPEL H, KUHNE M, SPIEKERMANN S et al.: Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum 2006; 54: 1805-13.
87. APPEL H, LODDENKEMPER C, MIOSSEC P: Rheumatoid arthritis and ankylosing spondylitis - pathology of acute inflammation. Clin Exp Rheumatol 2009; 27 (Suppl. 55): S15-9.
88. CHANG B, CASALI P: The CDR1 sequences of a major proportion of human germline Ig VH genes are inherently susceptible to amino acid replacement. Immunol Today 1994; 15: 367-73.
89. SHLOMCHIK MJ, AUCOIN AH, PISETSKY DS, WEIGERT MG: Structure and function of anti-DNA autoantibodies derived from a single autoimmune mouse. Proc Natl Acad Sci USA 1987; 84: 9150-4.
90. BAETEN D, KRUITHOF E, BREBAN M, TAK PP: Spondylarthritis in the absence of B lymphocytes. Arthritis Rheum 2008; 58: 730-3.
91. GORSKI J, YASSAI M, ZHU X et al.: Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J Immunol 1994; 152: 5109-19.
92. BORGATO L, BERI R, BIASI D et al.: Analysis of the T cell receptor repertoire in rheumatoid arthritis. Clin Exp Rheumatol 1997; 15: 475-9.
93. WEDDERBURN LR, PATEL A, VARSANI H, WOO P: Divergence in the degree of clonal expansions in inflammatory T cell subpopulations mirrors HLA-associated risk alleles in genetically and clinically distinct subtypes of childhood arthritis. Int Immunol 2001; 13: 1541-50.
94. DUCHMANN R, LAMBERT C, MAY E, HOHLER T, MARKER-HERMANN E: CD4+ and CD8+ clonal T cell expansions indicate a role of antigens in ankylosing spondylitis; a study in HLA-B27+ monozygotic twins. Clin Exp Immunol 2001; 123: 315-22.
95. TREVINO MA, TEIXEIRO E, BRAGADO R: CD8+ T cells oligoclonally expanded in synovial fluid at onset of spondyloarthropathy selectively proliferate in response to self-antigens: characterization of cell specificities in nonclonal populations. J Rheumatol 2004; 31: 1962-72.
96. MAY E, DULPHY N, FRAUENDORF E et al.: Conserved TCR beta chain usage in reactive arthritis; evidence for selection by a putative HLA-B27-associated autoantigen. Tissue Antigens 2002; 60: 299-308.
97. COSTELLO PJ, WINCHESTER RJ, CURRAN SA et al.: Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol 2001; 166: 2878-86.
98. TASSIULAS I, DUNCAN SR, CENTOLA M, THEOFILOPOULOS AN, BOUMPAS DT: Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 1999; 60: 479-91.
99. CURRAN SA, FITZGERALD OM, COSTELLO PJ et al.: Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol 2004; 172: 1935-44.
100. KINSELLA TD, ESPINOZA L, VASEY FB: Serum complement and immunoglobulin levels in sporadic and familial ankylosing spondylitis. J Rheumatol 1975; 2: 308-13.
101. VEYS EM, VAN LEARE M: Serum IgG, IgM, and IgA levels in ankylosing spondylitis. Ann Rheum Dis 1973; 32: 493-6.
102. COWLING P, EBRINGER R, EBRINGER A: Association of inflammation with raised serum IgA in ankylosing spondylitis. Ann Rheum Dis 1980; 39: 545-9.
103. DAVIS MJ, DAWES PT, BESWICK E, LEWIN IV, STANWORTH DR: Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin. Br J Rheumatol 1989; 28: 410-3.
104. FRANSSEN MJ, VAN DE PUTTE LB, GRIBNAU FW: IgA serum levels and disease activity in ankylosing spondylitis: a prospective study. Ann Rheum Dis 1985; 44: 766-71.
105. COLLADO A, SANMARTI R, SERRA C et al.: Serum levels of secretory IgA in ankylosing spondylitis. Scand J Rheumatol 1991; 20: 153-8.
106. MACKIEWICZ A, KHAN MA, REYNOLDS TL, VAN DER LINDEN S, KUSHNER I: Serum IgA, acute phase proteins, and glycosylation of alpha 1-acid glycoprotein in ankylosing Spondylitis. Ann Rheum Dis 1989; 48: 99-103.
107. TIWANA H, NATT RS, BENITEZ-BRITO R et al.: Correlation between the immune responses to collagens type I, III, IV and V and Klebsiella pneumoniae in patients with Crohn's disease and ankylosing spondylitis. Rheumatology (Oxford) 2001; 40: 15-23.
108. TANI Y, TIWANA H, HUKUDA S et al.: Antibodies to Klebsiella, Proteus, and HLA-B27 peptides in Japanese patients with ankylosing spondylitis and rheumatoid arthritis. J Rheumatol 1997; 24: 109-14.
109. WILSON C, THAKORE A, ISENBERG D, EBRINGER A: Correlation between antiProteus antibodies and isolation rates of P. mirabilis in rheumatoid arthritis. Rheumatol Int 1997; 16: 187-9.
110. BLANKENBERG-SPRENKELS SH, FIELDER M, FELTKAMP TE, TIWANA H, WILSON C, EBRINGER A: Antibodies to Klebsiella pneumoniae in Dutch patients with ankylosing spondylitis and acute anterior uveitis and to Proteus mirabilis in rheumatoid arthritis. J Rheumatol 1998; 25: 743-7.
111. LINDQVIST U, RUDSANDER A, BOSTROM A, NILSSON B, MICHAELSSON G: IgA antibodies to gliadin and coeliac disease in psoriatic arthritis. Rheumatology (Oxford) 2002; 41: 31-7.
112. TOROK HP, GLAS J, GRUBER R et al.: Inflammatory bowel disease-specific autoantibodies in HLA-B27-associated spondyloarthropathies: increased prevalence of ASCA and pANCA. Digestion 2004; 70: 49-54.
113. Aydin SZ, Atagunduz P, Temel M, Bicakcigil M, Tasan D, Direskeneli H: Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford) 2008; 47: 142-4. (Pubitemid 351168221)
114. HOFFMAN IE, DEMETTER P, PEETERS M et al.: Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis 2003; 62: 455-9.
115. RIENTE L, CHIMENTI D, PRATESI F et al.: Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. J Rheumatol 2004; 31: 920-4.
116. BENJAMIN M, MCGONAGLE D: The enthesis organ concept and its relevance to the spondyloarthropathies. Adv Exp Med Biol 2009; 649: 57-70.
117. MCGONAGLE D, LORIES RJ, TAN AL, BENJAMIN M: The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007; 56: 2482-91.
118. MCGONAGLE D, STOCKWIN L, ISAACS J, EMERY P: An enthesitis based model for the pathogenesis of spondyloarthropathy, additive effects of microbial adjuvant and biomechanical factors at disease sites. J Rheumatol 2001; 28: 2155-9.
119. MCGONAGLE D: Imaging the joint and enthesis: insights into pathogenesis of psoriatic arthritis. Ann Rheum Dis 2005; 64 (Suppl. 2): ii58-60.
120. HASLOCK I: Arthritis and Crohn's disease. A family study. Ann Rheum Dis 1973; 32: 479-86.
121. GREENSTEIN AJ, JANOWITZ HD, SACHAR DB: The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976; 55: 401-12.
122. MIELANTS H, VEYS EM, CUVELIER C et al.: Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthropathy - a prospective study. J Rheumatol 1993; 20: 1567-72.
123. MIELANTS H, VEYS EM, GOEMAERE S, GOETHALS K, CUVELIER C, DE VOS M: Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol 1991; 18: 1542-51.
124. DE VOS M, CUVELIER C, MIELANTS H, VEYS E, BARBIER F, ELEWAUTA: Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology 1989; 96: 339-44.
125. MIELANTS H, VEYS EM, CUVELIER C, DE VOS M: Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol 1988; 27 (Suppl. 2): 95-105.
126. MCGOVERN DP, GARDET A, TORKVIST L et al.: Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010; 42: 332-7.
127. BARRETT JC, HANSOUL S, NICOLAE DL et al.: Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-62.
128. PETTY RE, SOUTHWOOD TR, MANNERS P et al.: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
129. MIELANTS H, VEYS EM, GOETHALS K, VAN DER STRAETEN C, ACKERMAN C, GOEMAERE S: Destructive hip lesions in seronegative spondyloarthropathies: relation to gut inflammation. J Rheumatol 1990; 17: 335-40.
130. WRIGHT V, WATKINSON G: The arthritis of ulcerative colitis. Medicine (Baltimore) 1959; 38: 243-62.
131. MOLL JM, WRIGHT V: Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78.
132. SCHATTEMAN L, MIELANTS H, VEYS EM et al.: Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol 1995; 22: 680-3.
133. JACQUES P, ELEWAUT D, MIELANTS H: Interactions between gut inflammation and arthritis/spondylitis. Curr Opin Rheumatol 22: 368-74.
134. STEBBINGS S, MUNRO K, SIMON MA et al.: Comparison of the faecal microflora of patients with ankylosing spondylitis and controls using molecular methods of analysis. Rheumatology (Oxford) 2002; 41: 1395-401.
135. STEBBINGS SM, TAYLOR C, TANNOCK GW, BAIRD MA, HIGHTON J: The immune response to autologous bacteroides in ankylosing spondylitis is characterized by reduced interleukin 10 production. J Rheumatol 2009; 16: 191-800.
136. SMITH AM, RAHMAN FZ, HAYEE B et al.: Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 2009; 206: 1883-97.
137. NETEA MG, KULLBERG BJ, DE JONG DJ et al.: NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol 2004; 34: 2052-9.
138. NOGUCHI E, HOMMA Y, KANG X, NETEA MG, MA X: A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol 2009; 10: 471-9.
139. OGURA Y, BONEN DK, INOHARA N et al.: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6.
140. BAMIAS G, COMINELLI F: Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol 2007; 23: 365-9.
141. HUGOT JP, CHAMAILLARD M, ZOUALI H et al.: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
142. CASANOVA JL, ABEL L: Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J Exp Med 2009; 206: 1839-43.
143. PAPADAKIS KA, ZHU D, PREHN JL et al.: Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol 2005; 174: 4985-90.
144. BAMIAS G, MISHINA M, NYCE M et al.: Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad Sci U S A 2006; 103: 8441-6.
145. ZHAO C, WOOD MW, GALYOV EE et al.: Salmonella typhimurium infection triggers dendritic cells and macrophages to adopt distinct migration patterns in vivo. Eur J Immunol 2006; 36: 2939-50.
146. KIRVESKARI J, JALKANEN S, MAKI-IKOLA O, GRANFORS K: Increased synovial endothelium binding and transendothelial migration of mononuclear cells during Salmonella infection. Arthritis Rheum 1998; 41: 1054-63.
147. SAXENA N, MISRA R, AGGARWAL A: Is the enthesitis-related arthritis subtype of juvenile idiopathic arthritis a form of chronic reactive arthritis? Rheumatology (Oxford) 2006; 45: 1129-32.
148. PACHECO-TENA C, ALVARADO DE LA BARRERA C, LOPEZ-VIDAL Y et al.: Bacterial DNA in synovial fluid cells of patients with juvenile onset spondyloarthropathies. Rheumatology (Oxford) 2001; 40: 920-7.
149. GRANFORS K, JALKANEN S, VON ESSEN R et al.: Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med 1989; 320: 216-21.
150. ZAMBRANO-ZARAGOZA JF, DE JESUS DURAN-AVELAR M, RODRIGUEZ-OCAMPO AN et al.: The 30-kDa band from Salmonella typhimurium: IgM, IgA and IgG antibody response in patients with ankylosing spondylitis. Rheumatology (Oxford) 2009; 48: 748-54.
151. CONSTANTINIU S, ROMANIUC A, CHIRIAC R et al.: Antibacterial antibodies for some enterobacteria in sera of patients with reactive arthritis and other rheumatoid diseases. Roum Arch Microbiol Immunol 2008; 67: 30-5.
152. SINHA R, AGGARWAL A, PRASAD K, MISRA R: Sporadic enteric reactive arthritis and undifferentiated spondyloarthropathy: evidence for involvement of Salmonella typhimurium. J Rheumatol 2003; 30: 105-13.
153. MCGOVERN DP, GARDET A, TORKVIST L et al.: Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 42: 332-7.
154. VANDOOREN B, TAK PP, BAETEN D: Synovial and mucosal immunopathology in spondyloarthritis. Adv Exp Med Biol 2009; 649: 71-84.
155. MIELANTS H, VEYS EM, CUVELIER C et al.: The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995; 22: 2279-84.
156. ZOCHLING J, VAN DER HEIJDE D, DOUGADOS M, BRAUN J: Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/ EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006; 65: 423-32.
157. EMAD Y, RAGAB Y, SHAARAWY A et al.: Can magnetic resonance imaging differentiate undifferentiated arthritis based on knee imaging? J Rheumatol 2009; 36: 1963-70.
158. RUDWALEIT M, JURIK AG, HERMANN KG et al.: Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondylarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 2009; 68: 1520-7.
159. DAI J, LIU WZ, ZHAO YP, HU YB, GE ZZ: Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol 2007; 42: 1440-4.
160. D-INCA R, DAL PONT E, DI LEO V et al.: Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007; 22: 429-37.
161. SCHOEPFER AM, TRUMMLER M, SEEHOLZER P, SEIBOLD-SCHMID B, SEIBOLD F: Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14: 32-9.
162. CANANI RB, RAPACCIUOLO L, ROMANO MT et al.: Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis 2004; 36: 467-70.